CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: We previously reported a 75-probe gene expression signature derived from CD34+ cells of imatinib-naïve CP-CML patients that predicts major cytogenetic response (MCyR; <36% Ph+ metaphases) to imatinib [8].